Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Roche Pharma AG | INDUSTRY |
The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| laboratory biomarker analysis | Other | |||
| Next Generation Sequencing | Other | |||
| DNA Analysis | Genetic |
| Measure | Description | Time Frame |
|---|---|---|
| Mutation profiling of circulating tumor DNA from plasma samples. | To evaluate the sensitivity of NGS to detect the genetic alterations in plasma tumor DNA. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Quantity of circulating tumor DNA in serially collected plasma specimens. | To evaluate the change of quantity of circulating tumor DNA during treatment. | 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants will be recruited from patients receiving treatment for NSCLC at the Rennes Hospital
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean Mosser, PUPH | Rennes University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU | Rennes | 35000 | France |
Not provided
| ID | Term |
|---|---|
| D059014 | High-Throughput Nucleotide Sequencing |
| ID | Term |
|---|---|
| D017421 | Sequence Analysis |
| D005821 | Genetic Techniques |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided